Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Testing fractional doses of COVID-19 vaccines
Witold Więcek, Amrita Ahuja, Esha Chaudhuri, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 8
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Can Operation Warp Speed Serve as a Model for Accelerating Innovations beyond COVID Vaccines?
Arielle D’Souza, Kendall Hoyt, Christopher M. Snyder, et al.
Entrepreneurship and Innovation Policy and the Economy (2025) Vol. 4, pp. 103-138
Closed Access
Expanding capacity for vaccines against Covid-19 and future pandemics: a review of economic issues
Susan Athey, J. C. Castillo, Esha Chaudhuri, et al.
Oxford Review of Economic Policy (2022) Vol. 38, Iss. 4, pp. 742-770
Open Access | Times Cited: 19
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
Geert V.T. Roozen, Manon L. M. Prins, Corine Prins, et al.
Clinical Microbiology and Infection (2024)
Open Access | Times Cited: 2
Coagulation and inflammatory response after intramuscular or intradermal mRNA-1273 SARS-CoV-2 vaccine: secondary analysis of a randomized trial
Willian van Dijk, Margaretha Prins, Anna H.E. Roukens, et al.
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 8, Iss. 3, pp. 102419-102419
Open Access | Times Cited: 2
Predicting Efficacies of Fractional Doses of Vaccines by Using Neutralizing Antibody Levels: Systematic Review and Meta-Analysis
Zhanwei Du, Caifen Liu, Yuan Bai, et al.
JMIR Public Health and Surveillance (2024) Vol. 10, pp. e49812-e49812
Open Access | Times Cited: 2
Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population
Adam Abdullahi, James Opoku Frimpong, Mark T. K. Cheng, et al.
American Journal of Tropical Medicine and Hygiene (2023) Vol. 109, Iss. 4, pp. 890-894
Open Access | Times Cited: 6
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
Rapisa Nantanee, Puneyavee Aikphaibul, Peera Jaru-Ampornpan, et al.
Vaccine (2022) Vol. 40, Iss. 24, pp. 3320-3329
Open Access | Times Cited: 10
If You Build it, Will They Vaccinate? The Impact of COVID-19 Vaccine Sites on Vaccination Rates and Outcomes
John S. Brownstein, Jonathan Cantor, Benjamin G. Rader, et al.
(2022)
Open Access | Times Cited: 10
Vaccines and the Covid-19 pandemic: lessons from failure and success
Scott Duke Kominers, Alex Tabarrok
Oxford Review of Economic Policy (2022) Vol. 38, Iss. 4, pp. 719-741
Open Access | Times Cited: 10
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial
Chutima Seree-aphinan, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 73-73
Open Access | Times Cited: 1
Federated X-armed Bandit
Wenjie Li, Qifan Song, Jean Honorio, et al.
Proceedings of the AAAI Conference on Artificial Intelligence (2024) Vol. 38, Iss. 12, pp. 13628-13636
Open Access | Times Cited: 1
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
Thanyawee Puthanakit, Napaporn Chantasrisawad, Kirana Yoohat, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1646-1646
Open Access | Times Cited: 7
Dose optimisation and scarce resource allocation: two sides of the same coin
Garth W. Strohbehn, Govind Persad, William F. Parker, et al.
BMJ Open (2022) Vol. 12, Iss. 10, pp. e063436-e063436
Open Access | Times Cited: 7
Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India
Zhanwei Du, Lin Wang, Yuan Bai, et al.
Med (2023) Vol. 4, Iss. 3, pp. 182-190.e3
Open Access | Times Cited: 3
Targeted randomization dose optimization trials enable fractional dosing of scarce drugs
Philip S. Boonstra, Alex Tabarrok, Garth W. Strohbehn
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0287511-e0287511
Open Access | Times Cited: 3
A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine Development
Rajat Desikan, Massimiliano Germani, Piet H. van der Graaf, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 1, pp. 22-32
Open Access | Times Cited: 3
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Tsetsegsaikhan Batmunkh, Kerryn A. Moore, Helen Thomson, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 42, pp. 100953-100953
Open Access | Times Cited: 3
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
Rapisa Nantanee, Watsamon Jantarabenjakul, Peera Jaru-Ampornpan, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 914-914
Open Access | Times Cited: 4
Fractional Dosing of Yellow Fever Live Attenuated 17D Vaccine: A Perspective
Clairissa A. Hansen, J. Erin Staples, Alan D.T. Barrett
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 7141-7154
Open Access | Times Cited: 2
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, et al.
PLOS Global Public Health (2022) Vol. 2, Iss. 12, pp. e0001308-e0001308
Open Access | Times Cited: 3
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review
Oscar Espinosa, Laura Mora, Cristián Sanabria, et al.
Systematic Reviews (2024) Vol. 13, Iss. 1
Open Access
The economic way of thinking in a pandemic
Alex Tabarrok
The Journal of Economic Education (2024), pp. 1-7
Closed Access
Hierarchical Vaccine Allocation Based on Epidemiological and Behavioral Considerations
Satyaki Roy, Pratyay Dutta, Preetam Ghosh
IEEE/ACM Transactions on Computational Biology and Bioinformatics (2023) Vol. 20, Iss. 5, pp. 2981-2991
Closed Access | Times Cited: 1
How can COVID-19 vaccines benefit people? A study based on the theory of the commons
Yiqing Su, Yanyan Li, S. Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top